Compare Logitech International SA (LOGI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Twist Bioscience Corp — how do they compare? Logitech International SA trades at $104.46 (market cap $14.65B), while Twist Bioscience Corp trades at $93.87 (market cap $5.45B). The key difference: Logitech International SA is far larger — about 2.7× Twist Bioscience Corp's market cap, and Logitech International SA pays a 1.67% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| LOGI | TWST | |
|---|---|---|
Market Cap | $14.65B | $5.45B |
Sector | Technology | Health |
52-Week High | $126.69 | $102.88 |
52-Week Low | $85.84 | $24.16 |
Enterprise Value | $13.00B | $5.37B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.83, down 0.98% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals including a 14.69% net margin and consistent earnings beats. Recent product launches like the G3 Series and Spotlight 2 presenter highlight innovation, while a partnership with Call of Duty: Modern Warfare 4 boosts gaming segment prospects. Cash flow trends show operational strength with 2025 operating cash flow at $842.56M.
The stock offers upside to the $113 consensus price target, driven by B2B and AI product expansion, but faces risks from competitive pressures and reliance on consumer spending. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid valuation metrics like a P/E of 21.43.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
